By in-depth integration of in-house quality research resources, the Company has established a full-chain quality research platform compliant with regulatory requirements set forth by NMPA, FDA and EMA. The platform delivers end-to-end lifecycle management capabilities spanning early-stage drug discovery, clinical application submission through to commercial manufacturing, enabling scientific backing for the R&D and industrialization of innovative therapeutics including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs) and recombinant nanoparticle vaccines. 

It has built a closed-loop process development system covering druggability assessment of candidate molecules, high-yield cell line construction, upstream and downstream process development (cell culture, purification and formulation process scale-up), as well as technology transfer and commercial manufacturing to empower full-spectrum drug development. 

Furthermore, the Company has formulated study frameworks for forced degradation, compatibility stability and shipment simulation in alignment with ICH Q-series guidelines. Such setups concurrently support multi-jurisdictional registration filings in China, the US and Europe, facilitate global mutual recognition of comparability study data and strengthen the Group’s capacity for internationally compliant pharmaceutical research.